


## RESEARCH ARTICLE

# Heterozygous missense mutations in *NFATC1* are associated with atrioventricular septal defect

Rosangela Ferese<sup>1</sup> | Monica Bonetti<sup>2</sup> | Federica Consoli<sup>3</sup> | Valentina Guida<sup>3</sup> | Anna Sarkozy<sup>3</sup> | Francesca Romana Lepri<sup>4</sup> | Paolo Versacci<sup>5</sup> | Stefano Gambardella<sup>1</sup> | Giulio Calcagni<sup>4</sup> | Katia Margiotti<sup>3</sup> | Francesca Picci Sparascio<sup>3</sup> | Hossein Hozhabri<sup>3,6</sup> | Tommaso Mazza<sup>7</sup> | Maria Cristina Digilio<sup>4</sup> | Bruno Dallapiccola<sup>4</sup> | Marco Tartaglia<sup>4</sup> | Bruno Marino<sup>5</sup> | Jeroen den Hertog<sup>2,8</sup> | Alessandro De Luca<sup>3</sup> 

<sup>1</sup>IRCCS Neuromed, Localita' Camerelle, 86077 Pozzilli, Italy

<sup>2</sup>Hubrecht Institute-KNAW and University Medical Center Utrecht, 3584CT Utrecht, The Netherlands

<sup>3</sup>Molecular Genetics Unit, Casa Sollievo della Sofferenza Hospital, IRCCS, 71013 San Giovanni Rotondo, Italy

<sup>4</sup>Genetics and Rare Diseases Research Division, Bambino Gesù Children Hospital, IRCCS, 00146 Rome, Italy

<sup>5</sup>Division of Pediatric Cardiology, Department of Pediatrics, "Sapienza" University, 00161 Rome, Italy

<sup>6</sup>Department of Experimental Medicine, Sapienza University of Rome, 00161, Rome, Italy

<sup>7</sup>Bioinformatics Unit, Casa Sollievo della Sofferenza Hospital, IRCCS, 71013 San Giovanni Rotondo, Italy

<sup>8</sup>Institute of Biology, 2300RC Leiden, The Netherlands

## Correspondence

Alessandro De Luca, PhD, Istituto CSS-Mendel, Viale Regina Margherita 261, 00198 Rome, Italy. Email: a.deluca@css-mendel.it

## Funding information

Fondazione Bambino Gesù, Grant/Award Number: CUORE; Italian Ministry of Health, Grant/Award Numbers: RF 2010 2310935, RC 2016; Research Council for Earth and Life Sciences with financial aid from the Netherlands Organisation for Scientific Research (NWO), Grant/Award Number: ALW 819.02.021

Jeroen den Hertog and Alessandro De Luca equally contributed as senior authors in this work.

Communicated by Mark H. Paalman

## Abstract

Atrioventricular septal defect (AVSD) may occur as part of a complex disorder (e.g., Down syndrome, heterotaxy), or as isolated cardiac defect. Multiple lines of evidence support a role of calcineurin/NFAT signaling in AVSD, and mutations in *CRELD1*, a protein functioning as a regulator of calcineurin/NFAT signaling have been reported in a small fraction of affected subjects. In this study, 22 patients with isolated AVSD and 38 with AVSD and heterotaxy were screened for *NFATC1* gene mutations. Sequence analysis identified three missense variants in three individuals, including a subject with isolated AVSD [p.(Ala367Val)], an individual with AVSD and heterotaxy [p.(Val210Met)], and a subject with AVSD, heterotaxy, and oculo-auriculo-vertebral spectrum (OAVS) [p.(Ala696Thr)], respectively. The latter was also heterozygous for a missense change in *TBX1* [p.(Pro86Leu)]. Targeted resequencing of genes associated with AVSD, heterotaxy, or OAVS excluded additional hits in the three mutation-positive subjects. Functional characterization of *NFATC1* mutants documented defective nuclear translocation and decreased transcriptional transactivation activity. When expressed in zebrafish, the three *NFATC1* mutants caused cardiac looping defects and altered atrioventricular canal patterning, providing evidence of their functional relevance in vivo. Our findings support a role of defective *NFATC1* function in the etiology of isolated and heterotaxy-related AVSD.

## KEYWORDS

Atrioventricular septal defect, congenital heart defect, heterotaxy, *NFATC1*, oculo-auriculo-vertebral spectrum

## 1 | INTRODUCTION

Congenital heart defects (CHDs) are the most common birth defects worldwide, occurring in four to eight of 1,000 live births (Ferencz et al., 1985). In a significant fraction of cases, CHDs are caused by chromosomal anomalies or gene mutations, manifesting either as isolated disorder or as an associated defect in the context of a multisystem disease. CHDs with an established genetic cause account for less than 20% of cases, and the underlying molecular cause of the majority of isolated CHDs still remains uncharacterized.

Atrioventricular septal defect (AVSD; MIM# 606215) comprises a series of different anomalies of the atrioventricular valves, and atrial and ventricular septa. They represent up to 7% of all CHDs, and their prevalence ranges from 0.3 to 0.4 per 1,000 live births (Calkoen et al., 2016; Reller, Strickland, Riehle-Colarusso, Mahle, & Correa, 2008). Based on large fetal echocardiographic series, AVSD prevalence has been estimated to be much higher in utero, accounting for 18% of CHD affected fetuses. AVSD can be either complete or partial. The former represents approximately 70% of total AVSD cases, and in general consists of a single common atrioventricular valve and an atrial septal defect (ostium primum) confluent with a posterior ventricular septal defect in the inlet portion of the ventricular septum. In the partial form, including the remaining 30% of cases, two separate right and left atrioventricular valves (with a cleft of the anterior leaflet of the mitral valve) and an atrial septal defect (ostium primum), in absence of ventricular septal communication, are commonly observed. Isolated cleft of the mitral valve is considered a less severe form of AVSD (DiSegni, Pierpont, Bass, & Kaplinsky, 1985). In families of patients with AVSD, recurrence of CHD in siblings has been reported in 3–4% of cases (Digilio et al., 1993), supporting to a multifactorial model of inheritance. In a subset of families, however, recurrent CHD is prevalently concordant and transmission of the disease fits with an autosomal dominant model, with monogenic or oligogenic inheritance (Digilio et al., 1993).

Large studies estimate that more than two-thirds infants with AVSD display a cytogenetic abnormality, with trisomy 21 being the most common. In an unselected series of more than 600 patients, Down syndrome (DS; MIM# 190685) and heterotaxy syndrome (HTX; MIM# 606217) accounted for about 45 and 15% of AVSD cases, with other genetic or syndromic disorders representing an additional 15% (Digilio, Marino, Toscano, Giannotti, & Dallapiccola, 1999). In the same series, isolated AVSD accounted for 25% of affected individuals (Digilio et al., 1999). In addition to DS and HTX, other disorders having AVSD as associated feature include Ellis-van Creveld syndrome (MIM# 225500), Oro-Facio-Digital syndrome II (MIM# 252100), Kaufman-McKusick syndrome (MIM# 236700), Smith-Lemli-Opitz syndrome (MIM# 270400), CHARGE syndrome (MIM# 214800), and Noonan syndrome (MIM# 163950) (Digilio et al., 1999, 2018). AVSD typically occurs in patients with 8p23 and 3p25-26 deletion syndromes (Giglio et al., 2000; Green et al. 2000). Deletion 8p23 encompasses *GATA4* gene, which encodes for a transcription factor with important role in cardiac development, whose missense mutations have been reported in selected families with isolated AVSD (Garg et al., 2003). Deletion 3p25-26 comprises *CRELD1*, the first gene to be associated with AVSD

(Robinson et al., 2003). An additional locus for isolated AVSD has been mapped to chromosome 1p31-p21 (Sheffield et al., 1997), but the relevant disease gene still remains unknown. Moreover, dominant negative-acting mutations in the transforming growth factor-beta receptor *ALK2* have also been reported in AVSDs (Smith et al., 2009). Recently, application of next generation sequencing (NGS) to explore the molecular causes of AVSDs has allowed to identify rare causal variants in *NR2F2* (Al Turki et al., 2014) and other genes with biological relevance to AVSD (e.g., *NIPBL*, *CHD7*, *CEP152*, *BMPR1a*, *ZFPM2*, and *MDM4*) (D'Alessandro et al., 2016). Among these, mutations in *NIPBL*, *CHD7*, and *CEP152* have also been implicated in developmental disorders, further emphasizing their pleiotropic effect on development.

*NFATC1* is a member of the Rel/NF- $\kappa$ B family of transcription factors that were first reported as key regulators of T-cell activation. Five proteins of this family (*NFATC1–5*) are found in mammals, all playing nonredundant roles during embryonic and postnatal development (Wu, Baldwin, & Zhou, 2013). NFATs regulate proliferation, differentiation, and homeostasis in numerous cell types during embryogenesis and throughout life (Crabtree GR, 1999). *NFATC1* is required for cardiac development. Mice homozygous for a disrupted *Nfatc1* gene do not develop normal cardiac valves and septa, and die of circulatory failure during embryonic development (de la Pompa et al., 1998; Ranger et al. 1998). *NFATC1* gene mutations have not been linked to human diseases so far, but missense mutations in *CRELD1*, an important regulator of the calcineurin/NFATC1 signaling, were found to occur in approximately 5–10% of individuals with AVSD, including isolated AVSD (Guo et al., 2010; Posch et al., 2008; Robinson et al., 2003; Zatyka et al., 2005), AVSD in individuals with Down syndrome (Asim et al., 2018; Guo et al., 2010; Maslen et al., 2006), and AVSD in the context of HTX (Robinson et al., 2003; Zhian, Belmont, & Maslen, 2012). These data argue that defective NFATC1 function could contribute to AVSD, and prompted the search of *NFATC1* mutations in two cohorts of patients, including both isolated AVSD and AVSD associated with HTX. We report the identification of *NFATC1* rare variants in a small but significant proportion of cases of both cohorts. Using immunofluorescence and luciferase assays, we provide in vitro data documentation for defective/impaired function of the disease-associated mutants. Finally, we showed that expression of each of the *NFATC1* mutants causes heart defects in zebrafish embryos. Taken together, these data provide evidence for the requirement of proper NFATC1 function in cardiac development.

## 2 | METHODS

### 2.1 | Study cohort

The study cohort included 60 unrelated individuals with AVSD (30 males and 30 females) comprising 22 patients with nonsyndromic AVSD and 38 with AVSD in the context of HTX. Complete and partial AVSD were equally represented. Supporting Information Table S1 shows the demographic and clinical characteristics for each patient. Cardiovascular diagnosis was obtained by echocardiography in all cases. Standard cytogenetic and 22q11 deletion

analyses were performed on all subjects as previously described (Amati et al., 1995), excluding the presence of any chromosomal rearrangements and aneuploidies. All study participants had previously been tested for *CRELD1*, *GATA4*, *PTPN11*, and *NR2F2* mutations by either denaturing high-performance liquid chromatography (DHPLC) and/or direct DNA sequencing, excluding occurrence of causative mutations in these genes (Sarkozy et al., 2005, 2006; De Luca A. unpublished data). DNA samples from 870 unrelated and healthy population-matched individuals served as controls. Of these, 70 subjects were sequenced for the entire coding region of the *NFATC1* gene (NM\_006162.4) and its exon-intron junctions to examine the genetic variability of this gene in a group of ethnically matching healthy individuals. Informed consents were obtained from parents or guardians of both patients and controls. Research protocols and procedures were approved by the Institutional Review Board of the participating institutes.

## 2.2 | NFATC1 mutational analysis

Genomic DNA was extracted from peripheral blood with standard protocols. The coding exons and intronic stretches flanking the splice sites of the *NFATC1* gene were scanned by DHPLC and direct DNA sequencing. Primers and PCR and DHPLC conditions were available on request. Numbering for all the variants started at the adenine nucleotide (A) in the ATG initiation codon. For protein sequences, the codon for the initiator methionine was codon 1. The NCBI HomoloGene tool (<https://www.ncbi.nlm.nih.gov/homologene>) was used to analyze the level of conservation of sequence variants in orthologous genes. The functional impact of the identified amino acid substitutions was assessed in silico using the Combined Annotation Dependent Depletion (CADD) tool (Kircher et al., 2014), which scores the deleteriousness of variants by integrating multiple functional categories into one metric. Based on this metric, the bottom 90% of all single nucleotide variants (~8.6 billion, GRCh37/hg19) are compressed into (phred-like) scaled CADD units <10, while the top 10 to 1% (~774 million variants) display CADD scores between 10 and 20. Finally, a score  $\geq 20$  indicates the 1% most deleterious variants. To apply a cutoff on deleteriousness, CADD values above 15 were classified as deleterious (Kircher et al., 2014).

## 2.3 | Next generation sequencing

An opportunely designed custom TruSight One sequencing panel kit (Illumina, San Diego, CA, USA) was used to analyze a panel of 38 selected OMIM genes, including 20 genes related to HTX, 14 genes associated to AVSD, and 4 genes related to OAVS (Supporting Information Table S2). The enriched libraries were sequenced by a NextSeq 500 instrument (Illumina, San Diego, CA, USA). NGS data analysis was performed using an in-house implemented pipeline. In particular, we considered only novel or rare variants with a minor allele frequency < 1% in databases (dbSNP, GO-ESP, and ExAC). The candidate variant selection was carried out taking into account the available clinical data of the affected individual.

## 2.4 | Plasmid construction of NFATC1 expression vectors

For fluorescent microscopy analyses, full-length human *NFATC1* was subcloned into the pEGFP-N1 (kindly provided by Prof. Martin F. Schneider, University of Maryland School of Medicine, Baltimore, MD, USA), to introduce an enhanced green fluorescence protein (EGFP) tag at the C-terminus. *NFATC1* variants [p.(Val210Met), p.(Ala367Val), and p.(Ala696Thr)] were introduced by site-directed mutagenesis (QuikChange II XL, Stratagene, La Jolla, CA, USA). A nuclear localization signal (NLS; ProLysLysLysArgLysVal) was introduced in the *NFATC1*-EGFP construct (*Bam*HI) to promote efficient nuclear translocation of ectopically expressed proteins. For transactivation assays, the *NPPB* promoter (−36320 to −34624, hg19), which contains binding sites for NFAT proteins (Molkentin, Lu, Antos, Markham, & Richardson, 1998), was cloned upstream of the luciferase gene (*Xho*I-*Hind*III sites) of the pGL2 reporter plasmid (pGL2-NPPB-Luc). For in vivo studies, human *NFATC1* was cloned (*Cl*at/*Xba*I sites) in the pCS2+ expression vector (pCS2+-*NFATC1*). All constructs were verified by sequencing.

## 2.5 | Immunofluorescence studies

For immunofluorescent staining, COS-7 cells were transfected with wild-type *NFATC1*-pEGFP-N1 or each of the three mutants, p.(Val210Met), p.(Ala367Val), and p.(Ala696Thr), using Lipofectamine 2000 (Invitrogen Life Technologies, Carlsbad, CA, USA), as indicated by the manufacturer's protocol. In cotransfection experiments, COS-7 cells were transfected with equal amounts of the wild-type *NFATC1*-pEGFP-N1 expressing plasmid in combination with each of the three mutant constructs. Cells were fixed after 48 h with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and stained with red-fluorescent Alexa Fluor-568 phalloidin antibody (Molecular Probes, Eugene, OR, USA) for actin cytoskeleton detection. The extensively rinsed cover glass was then mounted on the microscope slide using Vectashield Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA). Imaging was performed on a Leica CTS SP1 AOBs confocal microscope (Leica Microsystems, Mannheim, Germany).

## 2.6 | Luciferase reporter gene assays

COS-7 cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum (Life Technologies, Grand Island, NY, USA). Cells at approximately 90% confluence were transfected with plasmids using Lipofectamine 2000 reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). As an internal control, pRL-TK, which expresses the Renilla luciferase, was used to normalize transfection efficiency. A total of 250 ng wild-type or mutant *NFATC1* construct was cotransfected with 50 ng pGL2-NPPB-Luc reporter and 5 ng pRL-TK control vector. To simulate heterozygosity of the mutations, cells were cotransfected with an equal amount of wild-type and each of the mutant *NFATC1* expression vectors. Cells were harvested and lysed 48 h after transfection, and then the Firefly and Renilla luciferase

activities were measured with the Dual-Glo luciferase assay system (Promega, Madison, WI, USA). All transfection experiments were conducted in triplicates and repeated at least three times independently. The activity of the *NPPB* promoter was presented as fold activation of Firefly luciferase relative to Renilla luciferase.

## 2.7 | Cytoplasmic and nuclear extractions

To induce the protein to translocate into the nucleus, COS-7 cells transfected with wild-type or each of the *NFATC1* mutants were treated with 3 mM ionomycin (Sigma-Aldrich, St. Louis, MO, USA) for 30 min, 24 h after transfection. Following transfection of the wild-type or mutant *NFATC1*-pEGFP-N1 construct and treatment with ionomycin,  $20 \times 10^6$  COS-7 cells were resuspended in buffer A (10 mM Hepes or Tris-HCl [pH 7.5], 40 mM KCl, 2 mM  $MgCl_2$ , 10% glycerol, 1 mM NaPPI, 1  $\mu$ g/mL pepstatin, 1  $\mu$ g/mL aprotinin, 1  $\mu$ g/mL leupeptin, 1 mM  $NaVO_4$ , 1 mM NaF, 1 mM PMSF), incubated on ice for 30 min, and centrifuged for 5 min. Cytoplasmic extracts were saved. Nuclear pellets were cleaned with 25 M sucrose buffer (25 M sucrose, 1 M  $MgCl_2$ , 1 M HEPES [pH 7.4]) and 35 M sucrose buffer (35 M sucrose, 1 M  $MgCl_2$ , 1 M HEPES [pH 7.4]). Then, pellets were resuspended in buffer B (10 mM Hepes or Tris-HCl [pH 7.5], 500 mM NaCl, 1% Triton-X100, 10% glycerol, 1 mM NaPPI, 1  $\mu$ g/mL pepstatin, 1  $\mu$ g/mL aprotinin, 1  $\mu$ g/mL leupeptin, 1 mM  $NaVO_4$ , 1 mM NaF, 1 mM PMSF), sonicated for 1 min, centrifuged, and saved.

## 2.8 | Western blotting

Immunoblotting was carried out using standard methodologies. For *NFATC1* protein detection, rabbit monoclonal anti-EGFP antibody (Cell Signaling Technology, New England Biolabs Biolabs, Hertfordshire, UK) was used as primary antibody. Mouse anti-GM130 monoclonal antibody (cis-Golgi Marker; Abcam Inc., Cambridge, MA, USA) was used as a control for the cytoplasmic extract, and rabbit monoclonal anti-H3 (Histone H3) antibody (Abcam Inc., Cambridge, MA, USA) was used as a control for proper nuclear extract. Secondary antibodies specific to mouse or rabbit were purchased from BD Bioscience Pharmaceutical (Franklin Lakes, NJ, USA). Blots were visualized by the enhanced chemiluminescence system (ECL Western Blotting Detection Kit, GE Healthcare Life Sciences, Little Chalfont, UK). Western blots were repeated a minimum of three times to confirm reproducibility. Densitometric analysis was performed using ImageJ software.

## 2.9 | Zebrafish embryo injections and in situ hybridization and histological analysis

Zebrafish were kept and the embryos were staged as described previously (Westerfield, 1993). All procedures involving experimental animals were approved by the local animal experiments committee and performed in compliance with local animal welfare laws, guidelines, and policies, according to National and European law. Wild-type and mutated (p.(Val210Met), p.(Ala367Val), and p.(Ala696Thr)) *NFATC1*

pCS2+ constructs were linearized with *NotI* enzyme and capped mRNA prepared with the Message Machine kit (Ambion, Austin, TX, USA). mRNA injections were performed at the one-cell stage. Morphological phenotypes were assessed at 24 and 48 h postfertilization (hpf). To investigate cardiac defects, embryos were anesthetized at 48 hpf with MS-222 (Sigma-Aldrich St. Louis, MO, USA), and fixed in 4% paraformaldehyde. In situ hybridizations were carried out as described previously (Thisse, Thisse, Schilling, & Postlethwait, 1993), using probes specific for the following heart proteins: cardiac myosin light chain 2 (*myl7*), atrial myosin heavy chain (*amhc*) (also known as *myh6*), ventricular myosin heavy chain (*vmhc*), atrial natriuretic factor (*anf*), bone morphogenetic protein 4 (*bmp4*), T-box transcription factor 2b (*tbx2b*), nuclear factor of activated T cells (*nfat*), and hyaluronan synthase 2 (*has2*). Embryos were cleared in methanol and mounted in 100% glycerol before pictures were taken. Phenylthiourea was added to suppress pigmentation in developing embryos at 48 hpf. To evaluate AVC formation, histological analysis of the heart was conducted on six injected embryos for the wild-type and each of the three mutants. Zebrafish embryos were mounted in Technovit 8100 (Kulzer, Wehrheim, Germany), and sections of 7  $\mu$ m thickness were cut with a microtome (Reichert-Jung 2050, Leica Microsystems, Wetzlar, Germany). Counterstaining was done using 0.05% neutral red, staining all nuclei. Sections were mounted in Pertex.

## 2.10 | Statistical analyses

Statistical analyses were performed using GraphPad Prism Software, version 5.0. Data were expressed as mean  $\pm$  SD, unless otherwise indicated. Continuous variables were tested for normal distribution and one-way ANOVA was used for the comparison of numeric variables between groups. Fisher's exact test was used to compare the number of individuals with rare (minor allele frequency < 1%) *NFATC1* variants between AVSD cases and controls. Student's t-test was used to establish statistical significance in luciferase experiments. A P-value < 0.05 indicated significant differences.

# 3 | RESULTS

## 3.1 | NFATC1 mutation screening

Overall 60 individuals with AVSD, including 22 subjects with nonsyndromic AVSD and 38 with AVSD in the context of HTX, were screened for *NFATC1* mutations by DHPLC analysis followed by confirmatory sequencing of positive DHPLC patterns. A total of 70 population-matched unaffected subjects were also screened as controls. Mutation screening allowed to identify three heterozygous *NFATC1* missense variants, two of which [p.(Val210Met) and p.(Ala696Thr)] were found in the subgroup of HTX patients (2/38, ~5.2%), and one, p.(Ala367Val), in the cohort of nonsyndromic AVSD cases (1/22, ~4.5%). No non-synonymous variant was identified in the control group (Fisher's exact test, one-tailed:  $P = 0.0957$ ). Parental DNA specimens were not available for any of the three probands. To exclude that the identified changes were variants occurring in the Italian population,



additional 1,600 population-matched unaffected control chromosomes were screened for the presence of those mutants by sequence analysis, and none carried the identified changes. p.(Val210Met), which was identified in a sporadic subject with partial AVSD and HTX with polysplenia (left isomerism), alters an evolutionarily conserved amino acid residue (Supporting Information Figure S1) within the N-terminal transactivation domain A (TAD-A, residues 126 to 218) that mediates NFATC1 binding to CREBBP/ EP300, a member of a family of coactivators involved in the regulation of transcription and chromatin remodeling (García-Rodríguez & Rao, 1998; Meissner et al., 2011). The change had been previously reported at very low MAF in public databases (c.628G > A, rs62096875), and was predicted to be high-impact variant (or deleterious) by CADD algorithm (scaled CADD score = 28.8). p.(Ala367Val) was found in a sporadic individual with nonsyndromic partial AVSD (CA12), and affected a moderately conserved amino acid (Supporting Information Figure S1) located in a region functionally uncharacterized and positioned downstream of the first nuclear export signal (NES; residues 310 to 321) and upstream of the second NLS (residues 682 to 684) of the protein. The missense change had previously been annotated in public databases (ESP6500 and ExAC) as a rare variant (c.1100C > T, rs367652299;  $MAF_{ESP6500} = 7.7E-5$ ,  $MAF_{ExAC} = 2.9E-5$ ) and was predicted to be a low-impact variant (or benign) by CADD bioinformatics tool (scaled CADD score = 9.984). The third variant, p.(Ala696Thr), was found in a sporadic patient with complete AVSD and both HTX with polysplenia (left isomerism) and oculo-auriculo-vertebral-spectrum (OAVS) as extra-cardiac findings. The variant affected a highly conserved amino acid residue (Supporting Information Figure S1) located close to the second NLS motif (residues 682–684), which mediates NFATC1 nuclear translocation. p.(Ala696Thr) had not previously been reported in public databases, and was predicted to be a high-impact variant (or deleterious) by CADD (scaled CADD score = 24.5). All of these mutations have been included in the LOVD database (<https://databases.lovd.nl/shared/variants/NFATC1/unique>).

DNA sequence chromatograms of the NFATC1 variants, corresponding predictions from bioinformatics tools and information on allele frequency in Italian controls and public databases, and anatomical characteristics of mutation-positive patients are summarized in Figure 1a–c.


To verify if NFATC1 mutation-positive patients carried genetic variations in other genes associated to AVSD, HTX, or OAVS, targeted resequencing was used to test a panel of 14 genes associated to AVSD, 20 genes involved in heterotaxy, and four genes associated to OAVS. No potentially pathogenic variant was found in patient CA12 with nonsyndromic partial AVSD and in patient HD239 with partial AVSD and HTX with polysplenia, whereas a likely pathogenic variant was detected in *TBX1* gene [NM\_080647.1: c.257C > T; p.(Pro86Leu)] in patient IS18 with complete AVSD and both HTX with polysplenia (left isomerism) and oculo-auriculo-vertebral-spectrum (OAVS). This *TBX1* missense change had previously been annotated in public databases (gnomAD exomes) as a rare variant (c.257C > T, rs775295536;  $MAF_{gnomAD} = 8.78838E-05$ ) and was predicted to be a high-impact variant (or deleterious) by bioinformatics tool (scaled CADD score = 21.4).

### 3.2 | In vitro functional characterization of the AVSD-associated NFATC1 mutants

NFATC1 is a transcription factor whose activity is controlled by the  $Ca^{2+}$ /Calmodulin-dependent phosphatase, calcineurin. Inactive NFATC1 resides in the cytoplasm. In response to sustained elevated calcium levels, NFATC1 is dephosphorylated by calcineurin, which induces rapid NFATC1 translocation to the nucleus, where it interacts with a variety of transcription factors to control expression of target genes (Rao, Luo, & Hogan, 1997). Since proper shuttling between cytoplasm and nucleus is essential for correct function of NFATC proteins, we first explored the impact of the three identified variants on NFATC1 subcellular localization. To this goal, immunofluorescence experiments were performed using COS-7 cells, which were transiently transfected to express either the wild-type or mutant EGFP-tagged NFATC1 proteins (Figure 2a). Following 48 h incubation, the analysis revealed that the wild-type protein localizes in the nucleus in steady state conditions. Conversely, localization of two disease-associated mutants, p.(Val210Met) and p.(Ala696Thr) remained restricted to the cytoplasm; similarly, incomplete nuclear translocation was also observed for the p.(Ala367Val) mutant. To confirm the aberrant subcellular localization of disease-associated mutants, NFATC1 subcellular localization was assessed after stimulation with ionomycin, a drug known to increase intracellular levels of  $Ca^{2+}$ , and expected to efficiently activate calcineurin, and consequently promote more effectively nuclear translocation of NFATC1. After stimulation with ionomycin, a large fraction of the p.(Ala367Val) and p.(Ala696Thr) NFATC1 proteins was retained in the cytoplasm, further documenting impaired nuclear translocation. Such aberrant localization was particularly apparent in the mutant carrying the p.(Val210Met) change. To explore the hypothesis that the observed defective/impaired nuclear translocation of the three mutants resulted from structural rearrangements affecting proper NLS recognition, subcellular localization of each mutant protein was assessed after transfecting cells with NFATC1 proteins containing an exogenous NLS at the N-terminus. Whereas the newly introduced NLS partially promoted nuclear import of the mutants, a large proportion of these proteins was still retained in the cytoplasm, confirming their variable impairment in the nuclear import.

To further validate this finding, immunoblot analysis of cytoplasmic and nuclear extracts was undertaken, before and after treatment with ionomycin. In both conditions, a nuclear-restricted localization was documented for wild-type NFATC1, while an aberrant distribution of mutants was observed. Consistent with the immunofluorescence analysis, the p.(Ala367Val) NFATC1 mutant was detected in both the cytoplasmic and nuclear fractions in untreated cells, while the other two mutants were present only in the cytoplasmic extract (Figure 2b). After treating cells for 30 min with 3 mM ionomycin, a large amount of the mutant proteins was still visible in the cytoplasmic fraction, confirming the profound impact of mutations on NFATC1 subcellular localization.

To simulate the heterozygous expression of variants occurring in affected subjects, equal amounts of wild-type and mutant constructs were cotransfected to COS-7 cells and subcellular localization of



**FIGURE 1** Nonsynonymous sequence variants in the *NFATC1* gene and their associated clinical characteristics. (a) DNA sequence chromatograms of *NFATC1* variants found in patients with AVSD. The arrow indicates the site of the variant nucleotide position. The wild-type and mutated sequences are shown below the electropherograms. (b) Annotation data for the nonsynonymous sequence variants detected in the *NFATC1* gene (RefSeq: NM\_006162.4): functional impact predictions from bioinformatics tools and information on allele frequency in Italian controls and public databases. (c) Clinical characteristics of mutation-positive patients


*NFATC1* was observed. Immunofluorescence studies showed that in cells coexpressing the wild-type protein concomitantly with each of the p.(Ala367Val) or p.(Ala696Thr) mutants the *NFATC1* protein product was present in both the cytoplasm and nucleus whereas most of the protein was localized in the cytoplasm in cells cotransfected with the p.(Val210Met) mutant (Figure 2c). These data support a heterogeneous behavior of *NFATC1* mutants with the p.(Val210Met) playing a dominant negative effect on wild-type *NFATC1*.

Impaired nuclear import of mutants would imply the presence of defective transcriptional control of target genes. To test this hypothesis the effect of each mutation on the transcriptional transactivation function of *NFATC1* was analyzed by measuring the efficiency in activation of the *NPPB* promoter by luciferase assays. As shown in Figure 3, wild-type *NFATC1* weakly activated the *NPPB* promoter basally, but more efficiently promoted the expression of the reported gene following treatment with 3 mM ionomycin. A similar extent of transactivation

was obtained in the *NFATC1* construct containing an additional NLS. In contrast, all mutants showed a variably reduced activation of the *NPPB* promoter, in all conditions. Consistent with the immunofluorescence and cell fractioning data, such defective transactivation was particularly evident in the p.(Ala696Thr) and p.(Val210Met) *NFATC1* mutants. To mimic the heterozygote condition, we co-transfected each mutant together with the wild-type and measured the luciferase reporter activity. When equimolar amounts of wild-type and mutant DNA were transfected into COS7 cells, all examined mutations caused a significant reduction of normal *NFATC1* activity, with p.(Val210Met) showing the most significant effect.

Together these results consistently suggest that AVSD-associated *NFATC1* mutants are inefficiently imported into the nucleus, have a significantly decreased transcriptional activity compared to the wild-type protein, and differentially impact on wild-type *NFATC1* function.

**FIGURE 2** Immunofluorescence localization and immunoblot analysis in COS-7 cells transfected with wild-type and mutant NFATC1 proteins [p.(Val210Met), p.(Ala367Val), and p.(Ala696Thr)]. (a) Immunofluorescence analysis was performed on cells treated without or with ionomycin (3 mM, 30 min), and on cells transfected with NFATC1-NLS constructs. NFAT proteins (green), phalloidin marking actin filaments (red), and the nucleus (blue) were visualized. (b) Immunoblot analysis of cytosolic and nuclear extracts before and after treatment with ionomycin. (c) Immunofluorescence localization analysis in COS-7 cells cotransfected with wild-type and each of the mutant NFATC1 proteins









FIGURE 2 Continued

3.3 | In vivo functional impact of the AVSD-associated NFATC1 mutants

In vitro assessment of the AVSD-associated *NFATC1* mutants provided evidence for the significant impact of the three identified missense changes on protein function. To explore the clinical relevance of the variants, the consequences of ectopic expression of each of the three

mutants on relevant developmental processes were analyzed in vivo using zebrafish as a model system. Wild-type or mutant mRNA was microinjected in zebrafish embryos at one-cell stage. The resulting phenotypes were investigated at 24 and 48 hpf. As shown in Figure 4a, expression of p.(Val210Met), p.(Ala367Val), or p.(Ala696Thr) *NFATC1* mRNA resulted in heart edema and increased yolk extension, whereas expression of GFP alone or wild-type *NFATC1* did not affect zebrafish





**FIGURE 3** Dual luciferase assays (expressed as fold activation of Firefly luciferase relative to Renilla luciferase) of COS-7 cells transfected with either wild-type or mutant NFATC1 proteins, in presence of the luciferase reporter constructs, basally (solid columns) and after treatment with ionomycin (dotted columns) or after adding to the protein an exogenous NLS (striped columns), or when wild-type protein was expressed in combination with each of the three mutants (checkered columns). Error bars for all data shown represent one SD and statistical significance was established by Student's *t*-test. Transfection control is an empty vector control. \*Indicates  $P < 0.05$  by *t*-test


development. No other obvious defects in other regions of embryos injected with mutant mRNAs were observed, indicating the cardiac-specific effects of the three NFATC1 mutations. To further characterize the cardiac phenotype in response to expression of NFATC1 variants, we examined the overall morphology and regionalization of the heart at 48 hpf by in situ hybridization, using a panel of cardiac markers, including *myl7* (heart tube), *amhc* (atrial myocardium), *vmhc* (ventricular myocardium), and *anf* (cardiac muscle cells). At this stage, the heart chambers are completely formed in wild-type embryos and the heart undergoes looping morphogenesis. As shown by *myl7* and *anf*-specific staining in embryos expressing mutant NFATC1 mRNAs, the heart tube looping was either accelerated [p.(Val210Met) and p.(Ala367Val)]- or retarded p.(Ala696Thr) compared to controls. In contrast, myocardial chamber specification did not appear to be affected in mutant embryos, as determined by expression of *vmhc* and *amhc*. Next, we used a panel of atrioventricular canal (AVC) marker genes (*bmp4*, *tbx2b*, *NFAT*, and *has2*) to evaluate the formation of the endocardial cushions, from which the atrioventricular valves develop. Compared to noninjected controls and wild-type NFATC1-expressing embryos, those expressing each of the three NFATC1 mutants showed altered expression of AVC marker genes (Figure 4b), indicating altered AVC specification domains in these embryos. To better delineate the consequences of the NFATC1 variants on AVC development, histological evaluation of the heart was performed. When compared to controls, all embryos injected with NFATC1 mutant transcripts displayed an abnormal cardiac structure (Figure 4c), confirming cardiac marker expression studies. Taken together, these data indicated that expression of

AVSD-associated NFATC1 alleles dramatically affected cardiac development by promoting abnormal heart looping and AVC development in a large proportion of embryos, without inducing gross defects in cardiac chamber specification.

## 4 | DISCUSSION

Here, we report that heterozygous private/rare variants in NFATC1 occur in a small proportion of isolated and syndromic AVSD cases. The identified missense changes result in a variably defective NFATC1 nuclear import and transcriptional function in vitro, and dramatically impact cardiac development in vivo, supporting their functional and clinical relevance. These results are in agreement with previous studies reporting the identification of NFATC1 variants and CNVs encompassing the gene in patients with various congenital heart defects, including ventricular septal defects and tricuspid atresia (Abdul-Sater et al., 2012; Feng et al., 2016; Gu et al., 2011; Han et al., 2010; Khalil et al., 2017; Li et al., 2017; Shen et al., 2013; Wang et al., 2016; Yehya, Souki, Bitar, & Nemer, 2006; Zhao et al., 2013). These results are also in agreement with previous identification of AVSD-related variants in CRELD1, a gene acting as a regulator of calcineurin/NFATC1 signaling by promoting NFATC1 dephosphorylation and translocation to the nucleus. Identification of functional variants in both NFATC1 and its upstream regulator CRELD1 is consistent with a relevant role of the calcineurin/NFATC1 signaling in altering cardiac developmental programs implicated in AVSD onset. Of note, similar to NFATC1 variants, which are present in both patients with isolated AVSD and with AVSD and HTX, heterozygous CRELD1 variants were also identified in both isolated and syndromic AVSD forms (Guo et al., 2010; Maslen et al., 2006; Posch et al., 2008; Robinson et al., 2003; Zatyka et al., 2005; Zhian et al., 2012). These findings suggest that in some instances both isolated and syndromic forms of AVSD share a common genetic etiology, although further work on larger patient cohorts is needed for confirmation. Considering that human CRELD1 mutations have also been identified as a risk genetic factor for AVSD in patients with DS, further studies are recommended to evaluate the presence and relevance of NFATC1 mutations in DS patients with AVSD as well.

The NFAT signaling cascade is critical for diverse aspects of mammalian development and physiology, including processes controlling cardiac development (Crabtree & Olson, 2002; de la Pompa et al., 1998; Ranger et al. 1998). An increase in intracellular  $Ca^{2+}$  concentration activates calcineurin, which dephosphorylates cytoplasmic NFAT proteins. Upon calcineurin-mediated dephosphorylation, nuclear localization signals are exposed, and NFAT proteins translocate to the nucleus (Crabtree & Olson, 2002). Once in the nucleus, NFAT proteins cooperate with each other or other transcription factors to regulate gene expression (Beals, Sheridan, Turck, Gardner, & Crabtree, 1997; Macian, 2005; Masuda et al., 1997; Okamura et al., 2000; Wu et al., 2013). We performed functional analysis of the three missense variants to determine the extent to which these residue substitutions affect normal cell localization and transcriptional activity of the protein. Immunofluorescence and transactivation experiments revealed that localization



**FIGURE 4** Zebrafish phenotype and heart characterization upon wild-type and mutant *NFATC1* RNA injection. (a) Lateral views of *NFATC1*-injected embryos at 24 hpf (A, wild-type; B, p.(Val210Met); C, p.(Ala367Val); D, p.(Ala696Thr)), and 48 hpf (A', wild-type; B', p.(Val210Met); C', p.(Ala367Val); D', p.(Ala696Thr)). Arrows indicate heart edemas and yolk sac extension sites. (b) Ventral views of 48 hpf embryos after in situ hybridization showing the expression of *myl7*, *amhc*, *vmhc*, *anf*, *bmp4*, *tbx2b*, *nfat*, and *has2* in wild-type and *NFATC1* mutant embryos. Numbers at the bottom right corner indicate the number of embryos displaying the illustrated phenotype vs. the total number of embryos examined. (c) Hematoxylin and eosin staining of transverse section of wild-type and mutant zebrafish.

of the p.(Val210Met) and p.(Ala696Thr) NFATC1 mutants remains restricted to the cytoplasm, and that these proteins display a significantly diminished transcriptional transactivation capacity. In contrast, the p.(Ala367Val) mutation was demonstrated to have milder impact on protein import to the nucleus. Consistent with the partially retained ability to translocate to the nucleus, this variant was shown to have a milder impact on the transcriptional function of NFATC1 compared to the other AVSD-related NFATC1 changes. Both p.(Val210Met) and p.(Ala696Thr) more dramatically affected NFATC1 transactivation activity. Such effect appeared to be enhanced when they were forced to enter the nuclei with ionomycin treatment or adding to the protein an exogenous NLS. Of note, p.(Val210Met) was demonstrated to drive a dominant negative behavior by impairing proper function of the wild-type protein by affecting its nuclear translocation upon stimulation. Further studies are required to understand whether the other two mutations have a qualitatively similar but milder dominant negative effect or result in a hypomorphic/inactive NFATC1 protein.

Whereas the p.(Ala367Val) variant was found in a patient with isolated AVSD, p.(Val210Met) and p.(Ala696Thr) were identified in syndromic patients with AVSD in the context of HTX with polysplenia. HTX is the most frequent extracardiac finding associated with AVSDs after trisomy 21 (Digilio et al., 1999), and refers to a combination of abnormal arrangement of the abdominal and thoracic organs with complex CHDs including AVSD, common atrium, anomalous systemic, and pulmonary venous drainage, persistent left superior vena cava with unroofed coronary sinus, and conotruncal defects. HTX is genetically heterogeneous and it has been associated to mutations in at least 20 genes involved in establishing left-right asymmetry, such as those encoding for transducers participating to NODAL signaling or those causing primary ciliary dyskinesia (PCD). In principle, mutation in these genes could plausibly be causal for both the cardiac and extracardiac phenotypic characteristics of the NFATC1-mutated patients. However, screening of a panel of disease genes implicated in AVSD, HTX, and OAVS was performed in the three NFATC1 mutation-positive cases, and none had genetic variations in major genes related to HTX, or showed the chronic respiratory tract infections typical of PCD, making unlikely this hypothesis. Nevertheless, given the complex and genetically heterogeneous architecture of AVSD, we cannot exclude that the identified NFATC1 variations and other undisclosed loci may jointly contribute to predisposition to AVSD in our cases. Interestingly, the variant exhibiting the milder phenotype, p.(Ala367Val) and partial maintainance of ability to translocate to the nucleus together with the highest transactivation activity among mutants, was found in a patient with isolated AVSD, while the other mutations, p.(Val210Met) and p.(Ala696Thr), which dramatically impacted the nuclear import and transactivation activity of the protein, were detected in patients with AVSD and HTX. These data suggest that different phenotypes might be associated to NFATC1 mutations, and such clinical heterogeneity might be the result of a quantitatively or qualitatively differential impact of mutations on NFATC1 function. We hypothesize that different thresholds of NFATC1 function might be required in various developmental programs, which would explain the differential involvement of the extracardiac manifestations, like HTX and/or the OAVS

phenotype, specifically associated with mutations with more severe impact on NFATC1 function. Of note, similarly to the NFATC1 mutations reported here, a selected group of mutations in cilia genes, with roles in both hedgehog signaling and laterality, can cause distinct presentations of AVSDs and HTX both in mice and humans, with the more severe mutations causing both AVSDs and situs abnormalities and the milder ones resulting in AVSDs in the absence of situs abnormalities (Burnicka-Turek et al., 2016).

During early embryogenesis, left-right asymmetry of the body-axis is established via intricate crosstalk among multiple signaling pathways, such as notch, nodal, hedgehog, FGF, and BMP, ultimately restricting NODAL signaling to the left side of the embryo (Andersen, Troelsen Kde, & Larsen, 2014). NODAL, LEFTY2, ACVR2B, GDF1, CFC1, CITED2, and ZIC3 expression has been localized to the laterality signaling pathway, and human mutations in these genes show a wide range of heart defects, many of which clustering around laterality defects, such as HTX and faulty heart looping (Andersen et al., 2014; De Luca et al., 2010). The association of NFATC1 mutations with enhanced susceptibility to AVSDs and laterality defects may be ascribed to a possible signaling intersection between the calcineurin-NFAT pathway and signaling pathways determining left-right asymmetry. Our in vivo studies showed that mutant zebrafish hearts are characterized by defective looping stage development and altered AVC patterning, indicating that the identified NFATC1 mutations do result in cardiac laterality defects when expressed in this animal model.

In addition to HTX, one of the NFATC1-mutated patient also presented features of OAVS, a nonrandom association of microtia, hemifacial microsomia with mandibular hypoplasia, ocular epibulbar dermoid, and cervical vertebral malformations (Gorlin, Jue, Jacobsen, & Goldschmidt, 1963; Rollnick, Kaye, Nagatoshi, Hauck, & Martin, 1987). Of note, AVSD is one of the CHDs more frequently associated with extracardiac anomalies (Ferencz, Loffredo, Corea-Villasenor, & Wilson, 1997), and CHDs have been reported in 5–58% of the OAVS patients, with AVSD in 2% of the cases (Calzolari et al., 2003; Digilio et al., 2008). Subjects with OAVS-HTX complex have recurrently been described, suggesting the possibility that OAVS in these patients represent a component of a malformation complex involving the organization of asymmetric structures (Caramia et al. 1970; Lin et al., 1998; Maat-Kievit, Baraitser, & Winter, 1994; Volpe & Gentile, 2004). Interestingly, further testing of the patient using a multigene NGS panel including candidate genes for AVSD, HTX, and OAVS identified an additional missense variant in *TBX1* gene, p.(Pro86Leu). *TBX1* encodes for a transcription factor of the T-box family, which plays important roles in the formation of tissues and organs during embryonic development. The gene maps to human chromosome 22q11.2, and changes in this gene, due to either a point mutation or a deletion of part of chromosome 22 encompassing *TBX1*, are considered to be responsible for many of the features of DiGeorge syndrome (DGS)/velocardiofacial syndrome (VCFS), a common congenital disorder characterized by neural-crest-related developmental defects. In the literature, 22q11.2 deletions have been also found to recur in patients with typical DGS/VCFS clinical features in association with hemifacial microsomia and microtia (Digilio et al., 2009; Dos Santos et al., 2014; Lafay-Cousin et al., 2009; Spineli-Silva, Bispo, Gil-da-Silva-Lopes, & Vieira, 2017; Torti, Braddock, Bernreuter,



& Batanian, 2013; Xu, Fan, & Siu, 2008), suggesting possible OAVS candidate genes in this segment. In view of these findings, *TBX1* variant p.(Pro86Leu) likely represents the major determinant of the OAVS phenotype in the present patient, and the gene within 22q11.2 chromosome responsible for the OAVS features observed in patients with 22q11.2 deletion.

The collected data point to a relationship between defective NFATC1 function and AVSD. Like most of CHDs, the presently identified NFATC1 mutated cases are sporadic. Beyond the 20% of sporadic CHD caused by de novo CNVs and SNVs, it is very likely that most CHDs are secondary to complex inheritance (Blue et al., 2017). Therefore, we cannot exclude that other genetic variants, including either common SNPs or rare/private mutants, are contributing to CHD found in these patients.

In summary, we identified three rare, nonsynonymous NFATC1 variants in patients with AVSD that significantly affect proper intracellular localization of the protein and its transcriptional activity, as well as the development of normal structure of the zebrafish heart. We also provided evidence for a dominant negative effect for one of the three variants. Taken together, these findings suggest that rare/private variants in NFATC1 gene contribute to the genetic underpinnings of AVSD in humans with situs solitus and HTX.

## ACKNOWLEDGMENTS

The authors wish to thank the patients who participated in this research. Funding: This work was supported with grant support from the Italian Ministry of Health (RF 2010 2310935 and RC 2016 to A.D.L.), a grant from the Research Council for Earth and Life Sciences [ALW 819.02.021] with financial aid from the Netherlands Organisation for Scientific Research (NWO) (to J.d.H.), and Fondazione Bambino Gesù (CUORE to M.T.).

## CONFLICT OF INTEREST

The authors declare that there is no conflict of interest regarding the publication of this article.

## AUTHOR CONTRIBUTIONS

Conception and design: R.F., A.S., J.d.H., A.D.L.

Analysis and interpretation: R.F., V.G., A.S., T.M., M.C.D., M.T., B.M., J.d.H., A.D.L.

Data collection: R.F., M.B., F.C., V.G., F.L., P.V., S.G., G.C., K.M., F.P.S., H.H., M.C.D.,

Obtained funding: M.T., J.d.H., A.D.L.

Overall responsibility: M.T., B.M., J.d.H., A.D.L.

## ORCID

Alessandro De Luca  <http://orcid.org/0000-0002-4408-8062>

## REFERENCES

Abdul-Sater, Z., Yehya, A., Beresian, J., Salem, E., Kamar, A., Baydoun, S., ... Nemer, G. (2012). Two heterozygous mutations in NFATC1 in a patient with Tricuspid Atresia. *PLoS One*, 7, e49532.

- Al Turki, S., Manickaraj, A. K., Mercer, C. L., Gerety, S. S., Hitz, M. P., Lindsay, S., ... Hurler, M. E. (2014). Rare variants in NR2F2 cause congenital heart defects in humans. *American Journal of Human Genetics*, 94, 574–585.
- Amati, F., Mari, A., Digilio, M. C., Mingarelli, R., Marino, B., Giannotti, A., ... Dallapiccola, B. (1995). 22q11 deletions in isolated and syndromic patients with tetralogy of Fallot. *Human Genetics*, 95, 479–482.
- Andersen, T. A., Troelsen Kde, L., & Larsen, L. A. (2014). Of mice and men: Molecular genetics of congenital heart disease. *Cellular and Molecular Life Sciences*, 71, 1327–1352.
- Asim, A., Agarwal, S., Panigrahi, I., Sarangi, A. N., Muthuswamy, S., & Kapoor, A. (2018). CRELD1 gene variants and atrioventricular septal defects in Down syndrome. *Gene*, 641, 180–185.
- Beals, C. R., Sheridan, C. M., Turck, C. W., Gardner, P., & Crabtree, G. R. (1997). Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. *Science (Washington, DC, United States)*, 75, 1930–1934.
- Blue, G. M., Kirk, E. P., Giannoulatos, E., Sholler, G. F., Dunwoodie, S. L., Harvey, R. P., & Winlaw, D. S. (2017). Advances in the genetics of congenital heart disease: A clinician's guide. *Journal of American College of Cardiology*, 69, 859–870.
- Burnicka-Turek, O., Steimle, J. D., Huang, W., Felker, L., Kamp, A., Kweon, J., ... Moskowitz, I. P. (2016). Cilia gene mutations cause atrioventricular septal defects by multiple mechanisms. *Human Molecular Genetics*, 25, 3011–3028.
- Calkoen, E. E., Hazekamp, M. G., Blom, N. A., Elders, B. B., Gittenberger-de Groot, A. C., Haak, M. C., ... Jongbloed, M. R. (2016). Atrioventricular septal defect: From embryonic development to long-term follow-up. *International Journal of Cardiology*, 202, 784–795.
- Calzolari, E., Garani, G., Cocchi, G., Magnani, C., Rivieri, F., Neville, A., ... Bosi, G. (2003). Congenital heart defects: 15 years of experience of the Emilia-Romagna Registry (Italy). *European Journal of Epidemiology*, 18, 773–780.
- Caramia, G., Di Battista, C., & Botticelli, A. (1970). Goldenhar's syndrome. Description of a case with cardiovascular abnormalities, right lung agenesis and situs viscerum inversus. *Minerva Pediatrica*, 22, 362–367.
- Crabtree, G. R. (1999). Generic signals and specific outcomes: Signaling through Ca<sup>2+</sup>, calcineurin, and NF-AT. *Cell (Cambridge, MA, United States)*, 96, 611–614.
- Crabtree, G. R., & Olson, E. N. (2002). NFAT signaling: Choreographing the social lives of cells. *Cell (Cambridge, MA, United States)*, 109(Suppl), S67–79.
- D'Alessandro, L. C., Al Turki, S., Manickaraj, A. K., Manase, D., Mulder, B. J., Bergin, L., ... Mital, S. (2016). Exome sequencing identifies rare variants in multiple genes in atrioventricular septal defect. *Genet Med*, 18, 189–198.
- de la Pompa, J. L., Timmerman, L. A., Takimoto, H., Yoshida, H., Elia, A. J., Samper, E., ... Mak, T. W. (1998). Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. *Nature (London, United Kingdom)*, 392, 182–186.
- De Luca, A., Sarkozy, A., Consoli, F., Feresé, R., Guida, V., Dentici, M. L., ... Dallapiccola, B. (2010). Familial transposition of the great arteries caused by multiple mutations in laterality genes. *Heart*, 96, 673–677.
- Digilio, M. C., Marino, B., Cicini, M. P., Giannotti, A., Formigari, R., & Dallapiccola, B. (1993). Risk of congenital heart defects in relatives of patients with atrioventricular canal. *American Journal of Disease of Children*, 147, 1295–1297.
- Digilio, M. C., Marino, B., Toscano, A., Giannotti, A., & Dallapiccola, B. (1999). Atrioventricular canal defect without Down syndrome: A heterogeneous malformation. *American Journal of Medical Genetics*, 85, 140–146.



- Digilio, M. C., Calzolari, F., Capolino, R., Toscano, A., Sarkozy, A., de Zorzi, A., ... Marino, B. (2008). Congenital heart defects in patients with oculo-auriculo-vertebral spectrum (Goldenhar syndrome). *American Journal of Medical Genetics A*, 146A, 1815–1819.
- Digilio, M. C., McDonald-McGinn, D. M., Heike, C., Catania, C., Dallapiccola, B., Marino, B., & Zackai, E. H. (2009). Three patients with oculo-auriculo-vertebral spectrum and microdeletion 22q11.2. *American Journal of Medical Genetics A*, 149A, 2860–2864.
- Digilio, M. C., Pugnaloni, F., De Luca, A., Calcagni, G., Baban, A., Dentici, M. L., ... Marino, B. (2018). Atrioventricular canal defect and genetic syndromes: The unifying role of Sonic Hedgehog. *Clinical Genetics*, May 3. <https://doi.org/10.1111/cge.13375>.
- DiSegni, E., Pierpont, M. E. M., Bass, J. L., & Kaplinsky, E. (1985). Two dimensional echocardiography in detection of endocardial cushion defect in families. *American J Cardiol*, 55, 1649–1652.
- Dos Santos, P. A., de Oliveira, S. F., Freitas, E. L., Safatle, H. P., Rosenberg, C., Ferrari, I., & Mazzeu, J. F. (2014). Non-overlapping 22q11.2 microdeletions in patients with oculo-auriculo-vertebral spectrum. *American Journal of Medical Genetics A*, 164A, 551–553.
- Feng, J., Hao, J., Chen, Y., Li, F., Han, J., Li, R., ... Wang, H. (2016). Chromosome microarray analysis of patients with 18q deletion syndrome. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*, 33, 203–207.
- Ferencz, C., Rubin, J. D., McCarter, R. J., Brenner, J. I., Neill, C. A., Perry, L. W., ... Downing, J. W. (1985). Congenital heart disease: Prevalence at live-birth. The Baltimore-Washington Infant Study. *American Journal of Epidemiology*, 121, 31–36.
- Ferencz, C., Loffredo, C. A., Corea-Villasenor, A., & Wilson, P. D. (1997). Left-sided obstructive lesions. In C. Ferencz, A. Correa-Villasenor, C. A. Loffredo, P. D. Wilson (Eds). *Genetic and environmental risks for major cardiovascular malformations: The Baltimore-Washington Infant Study 1981–1989* (pp. 165–225). Baltimore: Futura Publishing.
- García-Rodríguez, C., & Rao, A. (1998). Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP). *Journal of Experimental Medicine*, 187, 2031–2036.
- Garg, V., Kathiriyi, I. S., Barnes, R., Schluterman, M. K., King, I. N., Butler, C. A., ... Srivastava, D. (2003). GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. *Nature (London, United Kingdom)*, 424, 443–447.
- Giglio, S., Graw, S. L., Gimelli, G., Pirola, B., Varone, P., Voullaire, L., ... Zufardi, O. (2000). Deletion of a 5-cM region at chromosome 8p23 is associated with a spectrum of congenital heart defects. *Circulation*, 102, 432–437.
- Gorlin, R. J., Jue, K. L., Jacobsen, U., & Goldschmidt, E. (1963). Oculoauriculovertbral dysplasia. *Journal of Pediatrics*, 63, 991–999.
- Green, E. K., Priestley, M. D., Waters, J., Maliszewska, C., Latif, F., & Maher, E. R. (2000). Detailed mapping of a congenital heart disease gene in chromosome 3p25. *Journal of Medical Genetics*, 37, 581–587.
- Gu, H., Gong, J., Qiu, W., Cao, H., Xu, J., Chen, S., & Chen, Y. (2011). Association of a tandem repeat polymorphism in NFATc1 with increased risk of perimembranous ventricular septal defect in a Chinese population. *Biochemical Genetics*, 49, 592–600.
- Guo, Y., Shen, J., Yuan, L., Li, F., Wang, J., & Sun, K. (2010). Novel CRELD1 gene mutations in patients with atrioventricular septal defect. *World Journal of Pediatrics*, 6, 348–352.
- Han, Z. Q., Chen, Y., Tang, C. Z., Gao, W. G., Xie, J. Y., & Hu, D. Y. (2010). Association between nuclear factor of activated T cells 1 gene mutation and simple congenital heart disease in children. *Zhonghua Xin Xue Guan Bing Za Zhi*, 38, 621–624.
- Khalil, A., Al-Haddad, C., Hariri, H., Shibbani, K., Bitar, F., Kurban, M., ... Arabi, M. (2017). A novel mutation in FOXC1 in a Lebanese family with congenital heart disease and anterior segment dysgenesis: Potential roles for NFATC1 and DPT in the phenotypic variations. *Front Cardiovasc Med*, 4, 58.
- Kircher, M., Witten, D. M., Jain, P., O'Roak, B. J., Cooper, G. M., & Shendure, J. (2014). A general framework for estimating the relative pathogenicity of human genetic variants. *Nature Genetics*, 46, 310–315.
- Lafay-Cousin, L., Payne, E., Strother, D., Chernos, J., Chan, M., & Bernier, F. P. (2009). Goldenhar phenotype in a child with distal 22q11.2 deletion and intracranial atypical teratoid rhabdoid tumor. *American Journal of Medical Genetics A*, 149A, 2855–2859.
- Li, C. L., Niu, L., Fu, M. Y., Tian, J., Wang, Q. W., & An, X. J. (2017). Correlation between NFATC1 gene polymorphisms and congenital heart disease in children. *Eur Rev Med Pharmacol Sci*, 21, 3441–3446.
- Lin, H. J., Owens, T. R., Sinow, R. M., Fu, P. C. Jr, DeVito, A., Beall, M. H., ... Lachman, R. S. (1998). Anomalous inferior and superior venae cavae with oculoauriculovertbral defect: Review of Goldenhar complex and malformations of left-right asymmetry. *American Journal of Medical Genetics*, 75, 88–94.
- Maat-Kievit, J. A., Baraitser, M., & Winter, R. M. (1994). Total situs inversus associated with the oculo-auriculo-vertebral spectrum. *Clinical Dysmorphology*, 3, 82–86.
- Macian, F. (2005). NFAT proteins: Key regulators of T-cell development and function. *Nature Reviews Immunology*, 5, 472–484.
- Maslen, C. L., Babcock, D., Robinson, S. W., Bean, L. J., Dooley, K. J., Willour, V. L., & Sherman, S. L. (2006). CRELD1 mutations contribute to the occurrence of cardiac atrioventricular septal defects in Down syndrome. *American Journal of Medical Genetics A*, 140, 2501–2505.
- Masuda, E. S., Liu, J., Imamura, R., Imai, S. I., Arai, K. I., & Arai, N. (1997). Control of NFATx1 nuclear translocation by a calcineurin-regulated inhibitory domain. *Molecular and Cellular Biology*, 17, 2066–2075.
- Meissner, J. D., Freund, R., Krone, D., Umeda, P. K., Chang, K. C., Gros, G., & Scheibe, R. J. (2011). Extracellular signal-regulated kinase 1/2-mediated phosphorylation of p300 enhances myosin heavy chain I/beta gene expression via acetylation of nuclear factor of activated T cells c1. *Nucleic Acids Research*, 39, 5907–5925.
- Molkentin, J. D., Lu, J. R., Antos, C. L., Markham, B., Richardson, J., ... Olson, E. N. (1998). A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. *Cell (Cambridge, MA, United States)*, 93, 215–228.
- Okamura, H., Aramburu, J., García-Rodríguez, C., Viola, J. P., Raghavan, A., Tahiliani, M., ... Rao, A. (2000). Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. *Molecular Cell*, 6, 539–550.
- Posch, M. G., Perrot, A., Schmitt, K., Mittelhaus, S., Esenwein, E. M., Stiller, B., ... Berger, F. (2008). Mutations in GATA4, NKX2.5, CRELD1, and BMP4 are infrequently found in patients with congenital cardiac septal defects. *American Journal of Medical Genetics A*, 146A, 251–253.
- Ranger, A. M., Grusby, M. J., Hodge, M. R., Gravalles, E. M., de la Brousse, F. C., Hoey, T., ... Glimcher, L. H. (1998). The transcription factor NF-ATc is essential for cardiac valve formation. *Nature (London, United Kingdom)*, 1998;392, 186–190.
- Rao, A., Luo, C., & Hogan, P. G. (1997). Transcription factors of the NFAT family: Regulation and function. *Annual Review of Immunology*, 15, 707–447.
- Reller, M. D., Strickland, M. J., Riehle-Colarusso, T., Mahle, W. T., & Correa, A. (2008). Prevalence of congenital heart defects in metropolitan Atlanta, 1998–2005. *Journal of Pediatrics*, 153, 807–813.
- Robinson, S. W., Morris, C. D., Goldmuntz, E., Reller, M. D., Jones, M. A., Steiner, R. D., ... Cheryl, L. M. (2003). Missense mutations in CRELD1 are associated with cardiac atrioventricular septal defects. *American Journal of Human Genetics*, 72, 1047–1052.

- Rollnick, B. R., Kaye, C. I., Nagatoshi, K., Hauck, W., & Martin, A. O. (1987). Oculoauriculovertebral dysplasia and variants: Phenotypic characteristics of 294 patients. *American Journal of Medical Genetics*, 26, 361–375.
- Sarkozy, A., Esposito, G., Conti, E., Digilio, M. C., Marino, B., Calabrò, R., ... Dallapiccola, B. (2005). CRELD1 and GATA4 gene analysis in patients with nonsyndromic atrioventricular canal defects. *American Journal of Medical Genetics A*, 139, 236–238.
- Sarkozy, A., Lepri, F., Marino, B., Pizzuti, A., Digilio, M. C., & Dallapiccola, B. (2006). Additional evidence that PTPN11 mutations play only a minor role in the pathogenesis of non-syndromic atrioventricular canal defect. *American Journal of Medical Genetics A*, 140, 1970–1972.
- Sheffield, V. C., Pierpont, M. E., Nishimura, D., Beck, J. S., Burns, T. L., Berg, M. A., ... Lauer RM. (1997). Identification of a complex congenital heart defect susceptibility locus by using DNA pooling and shared segment analysis. *Human Molecular Genetics*, 6, 117–121.
- Shen, L., Li, Z. Z., Shen, A. D., Liu, H., Bai, S., Guo, J., ... Li, X. F. (2013). Association of NFATc1 gene polymorphism with ventricular septal defect in the Chinese Han population. *Chinese Medical Journal*, 126, 78–81.
- Smith, K. A., Joziassse, I. C., Chocron, S., van Dinther, M., Guryev, V., Verhoeven, M. C., ... Bakkers J. (2009). Dominant-negative ALK2 allele associates with congenital heart defects. *Circulation*, 119, 3062–3069.
- Spineli-Silva, S., Bispo, L. M., Gil-da-Silva-Lopes, V. L., & Vieira, T. P. (2017). Distal deletion at 22q11.2 as differential diagnosis in Craniofacial Microsomia: Case report and literature review. *European Journal of Medical Genetics*, 61(5), 262–268.
- Thisse, C., Thisse, B., Schilling, T. F., & Postlethwait, J. H. (1993). Structure of the zebrafish *snail1* gene and its expression in wild-type, spadetail and no tail mutant embryos. *Development (Cambridge, United Kingdom)*, 119, 1203–1215.
- Torti, E. E., Braddock, S. R., Bernreuter, K., & Batanian, J. R. (2013). Oculoauriculo-vertebral spectrum, cat eye, and distal 22q11 microdeletion syndromes: A unique double rearrangement. *American Journal of Medical Genetics A*, 161A, 1992–1998.
- Volpe, P., & Gentile, M. (2004). Three-dimensional diagnosis of Goldenhar syndrome. *Ultrasound in Obstetrics and Gynecology*, 24, 798–800.
- Wang, F., Wang, H., Wang, L., Zhou, S., Chang, M., Zhou, J., ... Shi, X. (2016). Association between single nucleotide polymorphisms in NFATC1 signaling pathway genes and susceptibility to congenital heart disease in the Chinese population. *Pediatric Cardiology*, 37, 1548–1561.
- Westerfield, M. (1993). *The zebrafish book: A guide for the laboratory use of zebrafish*. Eugene, OR: The University of Oregon Press.
- Wu, B., Baldwin, H. S., & Zhou, B. (2013). Nfatc1 directs the endocardial progenitor cells to make heart valve primordium. *Trends in Cardiovascular Medicine*, 23, 294–300.
- Xu, J., Fan, Y. S., & Siu, V. M. (2008). A child with features of Goldenhar syndrome and a novel 1.12 Mb deletion in 22q11.2 by cytogenetics and oligonucleotide array CGH: Is this a candidate region for the syndrome? *American Journal of Medical Genetics A*, 146A, 1886–1889.
- Yehya, A., Souki, R., Bitar, F., & Nemer, G. (2006). Differential duplication of an intronic region in the NFATC1 gene in patients with congenital heart disease. *Genome*, 49, 1092–1098.
- Zatyka, M., Priestley, M., Ladusans, E. J., Fryer, A. E., Mason, J., Latif, F., & Maher, E. R. (2005). Analysis of CRELD1 as a candidate 3p25 atrioventricular septal defect locus (AVSD2). *Clinical Genetics*, 67, 526–528.
- Zhao, W., Niu, G., Shen, B., Zheng, Y., Gong, F., Wang, X., ... Li, S. (2013). High-resolution analysis of copy number variants in adults with simple-to-moderate congenital heart disease. *American Journal of Medical Genetics A*, 161A, 3087–3094.
- Zhian, S., Belmont, J., & Maslen, C. L. (2012). Specific association of missense mutations in CRELD1 with cardiac atrioventricular septal defects in heterotaxy syndrome. *American Journal of Medical Genetics A*, 158A, 2047–2049.

## SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Ferese R, Bonetti M, Consoli F, et al. Heterozygous missense mutations in NFATC1 are associated with atrioventricular septal defect. *Human Mutation*. 2018;39:1428–1441. <https://doi.org/10.1002/humu.23593>